Table 3.
Treatment emergent adverse events reported in seven subjects.
| Number of subjects | Grade | Subject number* | |
|---|---|---|---|
| Fatigue | 5 | 1 | 2,3,5,6,10 |
| Injection site reactions** | 4 | 1 | 1,2,3,6 |
| Influenza-like illness | 2 | 1 | 5,6 |
| Headache | 1 | 1 | 10 |
| Diarrhea | 1 | 1 | 6 |
| Axillary pain | 1 | 1 | 10 |
| Rheumatoid factor increased | 1 | 1 | 5 |
| Nausea | 1 | 1 | 2 |
| Increased blood creatinine | 1 | 1 | 10 |
| Hematochezia | 1 | 1 | 5 |
| Eye infection | 1 | 1 | 2 |
| Insomnia | 1 | 1 | 3 |
| Squamous cell carcinoma | 1 | 2 | 1 |
| Gastroesophageal reflux disease | 1 | 2 | 10 |
| GI pain | 1 | 3 | 2 |
| Appendicitis | 1 | 3 | 9 |
| Cholecystitis | 1 | 3 | 2 |
| Anemia | 1 | 1 | 5 |